Skip to main content

Table 4 Postoperative complications and adverse events

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

 

Total (n = 38)

Postoperative complications

Nausea

11 (28.9%)

Pain

11 (28.9%)

Vomiting

3 (7.9%)

Fever

4 (10.5%)

Adverse events

Grade 3–4 adverse events

7 (18.4%)

Hand-foot syndrome

8 (21.1%)

Anemia

4 (10.5%)

Leukopenia

4 (10.5%)

Thrombocytopenia

5 (13.2%)

Elevated aspartate transaminase

4 (10.5%)

Hyperbilirubinemia

2 (5.3%)

Diarrhea

4 (10.5%)

Nausea

1 (2.6%)

Hypertension

2 (5.3%)

Rash

2 (5.3%)